HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.

Abstract
Nerve growth factor (NGF) is involved in pain transduction mechanisms and plays a key role in many persistent pain states, notably those associated with inflammation. On this basis, both the NGF ligand and its receptor TrkA (tyrosine kinase A) represent an eligible target for pain therapy. Although the direct involvement of NGF in pain modulation is well established, the effect of a direct functional block of the TrkA receptor is still unknown. In this study, we have demonstrated that MNAC13, the only anti-TrkA monoclonal antibody for which function neutralizing properties have been clearly shown both in vitro and in vivo, induces analgesia in both inflammatory and neuropathic pain models, with a surprisingly long-lasting effect in the latter. The formalin-evoked pain licking responses are significantly reduced by the MNAC13 antibody in CD1 mice. Remarkably, treatment with the anti-TrkA antibody also produces a significant antiallodynic effect on neuropathic pain: repeated i.p. injections of MNAC13 induce significant functional recovery in mice subjected to sciatic nerve ligation, with effects persisting after administration. Furthermore, a clear synergistic effect is observed when MNAC13 is administered in combination with opioids, at doses that are not efficacious per se. This study represents a direct demonstration that neutralizing antibodies directed against the TrkA receptor may display potent analgesic effects in inflammatory and chronic pain.
AuthorsGabriele Ugolini, Sara Marinelli, Sonia Covaceuszach, Antonino Cattaneo, Flaminia Pavone
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 104 Issue 8 Pg. 2985-90 (Feb 20 2007) ISSN: 0027-8424 [Print] United States
PMID17301229 (Publication Type: Journal Article)
Chemical References
  • Analgesics, Opioid
  • Antibodies, Monoclonal
  • MNAC13 monoclonal antibody
  • Formaldehyde
  • Nerve Growth Factor
  • Receptor, trkA
Topics
  • 3T3 Cells
  • Analgesics, Opioid (pharmacology)
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Binding Sites, Antibody (drug effects)
  • Disease Models, Animal
  • Formaldehyde
  • Humans
  • Inflammation (drug therapy)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Nerve Growth Factor (metabolism)
  • Neutralization Tests
  • Pain (chemically induced, drug therapy)
  • Receptor, trkA (chemistry, immunology)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: